MetaSystems proudly announces the opening of our first subsidiary in the Southern hemisphere. The new office is located in Buenos Aires, Argentina and bears the name MetaSystems Latinoamérica SAS (MetaSystems LatAm). The foundation has been the response to the growing demand on technical knowledge and 'know how' experienced in the last years all over the Latin American territories. MetaSystems LatAm takes care for the organization of sales, support, and customer relation activities in all countries in Latin America. It will manage distributor companies and contacts in the region, and it will facilitate communication between end-users, distributors and headquarters in Germany.
XL RARA BA
Break Apart Probe
- Order Number
- Package Size
- 100 µl
Acute promyelocytic leukemia (APL) is considered as a subtype of acute myeloid leukemia (AML) and accounts for about 5-8% of all AML cases. The most frequent aberration in APL is t(15;17) which results in the formation of the promyelocytic leukemia (PML) - retinoic acid receptor alpha (RARA) fusion gene (PML-RARA). Around 98% of all APL cases are characterized by PML-RARA whereas translocations affecting RARA and other genes have been identified in only 1-2% of APL cases. Known fusion genes are ZBTB16-RARA, NPM1-RARA, NUMA1-RARA, STAT5B-RARA, PRKAR1A-RARA, BCOR-RARA and FIP1L1-RARA. ZBTB16-RARA comprises about 0.8% of all APL cases, the other rare fusions occur with lower frequency. Cryptic rearrangements resulting in the PML-RARA fusion gene are observed regularly, but also insertions of RARA into other locations have been found in a minority of APL cases. RARA is a nuclear hormone receptor which forms heterodimers with the retinoid X receptor alpha and is involved in the regulation of promyelocyte differentiation. RARA fusion genes interfere with myeloid differentiation and contribute in the development of APL. The majority of APL patients are responsive to therapeutic doses of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) associated with chemotherapeutic drug regimen. Patients with ZBTB16-RARA or STAT5B-RARA fusions are resistant to ATRA and ATO. The FISH break apart assay is a valuable tool for the detection of RARA rearrangements independent of the translocation partner.
- Acute Myelogenous Leukemia (AML)
Two green-orange fusion signals (2GO).
Aberrant Cell (typical results):
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the respective locus.
- Grimwade et al (2000) Blood 15:1297-1308
- Schoch et al (2002) Hematol J 3:259-263
- Adams and Nassiri (2015) Arch Pathol Lab Med 139:1308-1313